Table 4.
Selected trials of elranatamab in multiple myeloma (MM).
| Trial ID (References) | Drugs | Phase | Enrollment (N) | Trial Title |
|---|---|---|---|---|
| NCT03269136 [109,110] | Elran + (Dex or Len or Pom) | I | 101 | Open Label Study To Evaluate The Safety, Pharmacokinetic, Pharmacodynamic And Clinical Activity Of Elranatamab (PF-06863135), A B-Cell Maturation Antigen (BCMA) X CD3 Bispecific Antibody, As A Single Agent And In Combination with Immunomodulatory Agents In Patients with RRMM (MagnetisMM-1) |
| NCT04649359 [108] | Elran | II | 187 | Open-Label, Multicenter, Non-Randomized Study Of Elranatamab (Pf-06863135) Monotherapy In Participants with MM Who Are Refractory To At Least One Proteasome Inhibitor, One Immunomodulatory Drug And One Anti-CD38 Antibody (MagnetisMM-3) |
| NCT05090566 [111] | (Elran + Niro) vs. (Elran + Len + Dex) | II | 105 | Open Label Umbrella Study Of Elranatamab (PF-06863135), A B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, In Combination with Other Anti-Cancer Treatments In Participants with MM (MagnetisMM-4) |
| NCT05020236 [112,113] | Elran vs. (Elran + Dara) vs. (Dara + Pom + Dex) | III | 589 | Open-Label, 3-Arm, Multicenter, Randomized Study To Evaluate The Efficacy And Safety Of Elranatamab (PF-06863135) Monotherapy And Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone In Participants with RRMM Who Have Received At Least 1 Prior Line Of Therapy Including Lenalidomide And A Proteasome Inhibitor (MagnetisMM-5) |
| NCT05623020 | (Elran + Dara + Len) vs. (Dara + Len + Dex) | III | 966 | Open-Label, 2-Arm, Multicenter, Randomized Study To Evaluate The Efficacy And Safety Of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone In Transplant-Ineligible Participants with NDMM (MagnetisMM-6) |
| NCT05317416 [114] | Elran vs. Len | III | 760 | Randomized, 2-Arm Study Of Elranatamab (PF-06863135) Versus Lenalidomide In Patients NDMM After Undergoing ASCT (MagnetisMM-7) |
| NCT05014412 | Elran vs. Elran + Dex | I/II | 76 | Open-Label, Multicenter Study To Evaluate A Dosing Regimen with Two Step-Up Priming Doses And Longer Dosing Intervals Of Elranatamab (PF-06863135) Monotherapy In Participants with RRMM (MagnetisMM-9) |
ASCT = autologous stem cell transplantation; Dara = daratumumab; Dex = dexamethasone; Elran = elranatamab; Len = lenalidomide; MM = multiple myeloma; NDMM = newly diagnosed MM; Niro = nirogacestat; Pom = pomalidomide; RRMM = relapsed and/or refractory MM.